Cours de haut niveau sur les cellules souches Octobre 2006

Creation of a Biomanufacturing Center for recombinant proteins and ®monoclonal antibodies at Genopole st ®Evry (France), September 21 2006 – The Genopole biopark and the MAbgène company have announced the signature of a collaboration agreement for the creation and operation of a biomanufacturing center on ®the Genopole Evry bioccluster. By late 2007, the Center will produce recombinant proteins and monoclonal antibodies to GMP* standards for use in preclinical testing and Phase I & II clinical trials. The objective is to promote the development of the cluster's biotech companies, meet the needs of research labs & institutes and offer an alternative production source to pharmaceutical companies. This marks an ®important step in Genopole's industrial development: by operating in synergy with the existing ®Généthon viral vector production unit, the new Center and its associated projects will position Genopole as the benchmark for biomanufacturing in France. * Good Manufacturing Practice Meeting market needs and helping France make up ground This project meets a real market requirement in terms of production capacity: The world biopharmaceutical market (with a forecast turnover of 114 billion USD by 2010, 14% of the global pharma market) is generating ®significant demand and France is lagging behind in terms of clinical-grade biomanufacturing sites. The Genopole Biomanufacturing Center in Evry should meet the needs of French and Europe-based ...